HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hawaii's Proposed Oxybenzone Sunscreen Ban Fails Science Test – CHPA

This article was originally published in The Pink Sheet & The Rose Sheet

Executive Summary

CHPA commits to fighting against onslaught of bills in Hawaii aiming to ban or limit the use of oxybenzone-containing sunscreens, says CEO and President Scott Melville during his address on 2017 priorities during the CHPA Annual Executive Conference in Amelia Island, Fla. March 21.

You may also be interested in...



Key West Weighing Oxybenzone/Octinoxate Sunscreen Ban Per Hawaii’s Example

The Florida island city could be the next jurisdiction to prohibit the sale of oxybenzone- and octinoxate-containing sunscreens. Industry maintains that available science does not clearly link the ingredients to coral decline, with the Personal Care Products Council asking to present before the Key West City Commission at its January meeting.

Hawaii Bills Seek Ban On Oxybenzone-Containing Sunscreens

Hawaiian legislators have oxybenzone-containing sun-care products in their sights owing to research linking the UV filter to harmful effects on coral. Bills with momentum behind them in the Aloha State’s House and Senate propose related sales bans or warnings on product advertisements and displays.

OTC Monograph Application Reviews Get Deadlines, Not GRASE Flexibility

Changes to FDA's interpretation of the GRASE standard it uses to evaluate ingredient proposals would go further to opening the US monograph process to innovation and progress than setting deadlines for the reviews, industry stakeholders say.

Related Content

Topics

UsernamePublicRestriction

Register

RS122738

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel